Condition: Refractory Autoimmune Diseases · Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Brigham And Womens Hospital | Boston, Massachusetts, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Local Institution - 0007 | Camperdown, New South Wales, Australia | Withdrawn |
| Local Institution - 0008 | Brisbane, Queensland, Australia | Withdrawn |
| Local Institution - 0013 | Clayton, Victoria, Australia | Withdrawn |
| Local Institution - 0040 | Salvador, Estado de Bahia, Brazil | Not Yet Recruiting |
| Local Institution - 0039 | Porto Alegre, Brazil | Not Yet Recruiting |
| Local Institution - 0038 | São Paulo, Brazil | Not Yet Recruiting |
| Local Institution - 0004 | Prague, Praha 5, Czechia | Not Yet Recruiting |
| Revmatologicky ustav | Prague, Czechia | Recruiting |
| CHU Strasbourg-Hautepierre | Strasbourg, Alsace, France | Recruiting |
| Hopital Claude Huriez - CHU de Lille | Lille, Nord, France | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07115745